{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:29:57Z","timestamp":1764754197901,"version":"3.46.0"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,6,19]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze antimicrobial use and serious infections (SI) among patients with psoriatic arthritis (PsA) before and after initiating tumor necrosis factor inhibitor (TNFi) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this nationwide matched cohort study, we extracted data on patients with PsA initiating TNFi from 2005 to 2018 from the ICEBIO registry and matched them by age, sex, and calendar time to 5 randomly selected comparators from the general population. All filled prescriptions for antimicrobials, glucocorticoids, and methotrexate 2 years before and after initiating TNFi treatment were extracted from the Icelandic Prescription Medicines Register. All infection-related hospitalizations, a proxy for SI, were extracted from the Icelandic Hospital Discharge Register.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 399 PsA patients and 1986 matched comparators. Patients received more antimicrobial prescriptions before TNFi treatment, with a mean number of prescriptions per year of 1.26 vs 0.60 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). The mean number of prescriptions increased to 1.64 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) in the 12 months following TNFi initiation but returned to baseline thereafter. No statistically significant increase in SI was found. Adjusted for covariates, patients with PsA had a hazard ratio of 1.43 (95% CI 1.18-1.72,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) for receiving a prescription for antimicrobials following TNFi treatment initiation compared to before TNFi treatment. The risk was increased in the first year after treatment initiation but not in the second year, suggesting a transient effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Following TNFi initiation, antimicrobial use rose temporarily, with no significant increase in SI. These results support the safety of TNFi in PsA management, and the risk of SI should not weigh heavily in treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0029","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:35:14Z","timestamp":1752586514000},"page":"1098-1106","source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-3398","authenticated-orcid":false,"given":"Telma","family":"Thrastardottir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-7015","authenticated-orcid":false,"given":"Aron Hjalti","family":"Bjornsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-1059","authenticated-orcid":false,"given":"Arna","family":"Hauksdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-7476","authenticated-orcid":false,"given":"Sigurdur Yngvi","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-6505","authenticated-orcid":false,"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2680-6120","authenticated-orcid":false,"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025120301250843000_52.11.1098.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.008"},{"key":"2025120301250843000_52.11.1098.2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025120301250843000_52.11.1098.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025120301250843000_52.11.1098.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20496"},{"key":"2025120301250843000_52.11.1098.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073932"},{"key":"2025120301250843000_52.11.1098.6","first-page":"788","article-title":"Throat infections are associated with exacerbation in a substantial proportion of patients with chronic plaque psoriasis","volume":"96","author":"Thorleifsdottir","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2025120301250843000_52.11.1098.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210006"},{"key":"2025120301250843000_52.11.1098.8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/rheumatology\/keac253","article-title":"Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen","volume":"62","author":"Thrastardottir","year":"2023","journal-title":"Rheumatology"},{"key":"2025120301250843000_52.11.1098.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140067"},{"key":"2025120301250843000_52.11.1098.10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10067-021-05893-3","article-title":"Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study","volume":"41","author":"Karadag","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025120301250843000_52.11.1098.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025120301250843000_52.11.1098.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"2025120301250843000_52.11.1098.13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/acr2.11382","article-title":"Outpatient use of antimicrobials in patients with rheumatoid arthritis before and after treatment with tumor necrosis factor inhibitors: A nationwide retrospective cohort study","volume":"4","author":"Bjornsson","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025120301250843000_52.11.1098.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221007"},{"key":"2025120301250843000_52.11.1098.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"2025120301250843000_52.11.1098.16","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/jdv.18407","article-title":"Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials","volume":"36","author":"Wang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025120301250843000_52.11.1098.17","doi-asserted-by":"crossref","first-page":"2442603","DOI":"10.1155\/2022\/2442603","article-title":"Risk of candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"key":"2025120301250843000_52.11.1098.18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","article-title":"Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Yiu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2025120301250843000_52.11.1098.19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025120301250843000_52.11.1098.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216102"},{"key":"2025120301250843000_52.11.1098.21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/PTT.S161522","article-title":"Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry","volume":"8","author":"Gudbjornsson","year":"2018","journal-title":"Psoriasis"},{"key":"2025120301250843000_52.11.1098.22","doi-asserted-by":"crossref","unstructured":"Gudmundsson LS , Einarsson O , Johannsson M. Icelandic medicines registry (IMR). In: Trifiro G , Ientile V , Sultana J , Tari MG , editors. Databases for pharmacoepidemiological research. Cham: Springer; 2021:205-11.","DOI":"10.1007\/978-3-030-51455-6_17"},{"key":"2025120301250843000_52.11.1098.23","unstructured":"World Health Organization . Anatomical Therapeutic Chemical (ATC) classification. [Internet. Accessed February 9, 2022.] Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"},{"key":"2025120301250843000_52.11.1098.24","unstructured":"World Health Organization . Defined daily dose (DDD). [Internet. Accessed February 9, 2022.]. Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd"},{"key":"2025120301250843000_52.11.1098.25","unstructured":"Directorate of Health . [Hospital Discharge Register]. [Article in Icelandic.] [Internet. Accessed November 9, 2022.] Available from: https:\/\/island.is\/sjukrahus-og-starfsstodvar-heilbrigdisstarfsfolks-tolur\/um-toelfraedi-sjukrahusa-og-sjalfstaett-starfandi"},{"key":"2025120301250843000_52.11.1098.26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/14034948211059974","article-title":"Validity of chronic disease diagnoses in Icelandic healthcare registries","volume":"51","author":"R\u00f6gnvaldsson","year":"2023","journal-title":"Scand J Public Health"},{"key":"2025120301250843000_52.11.1098.27","unstructured":"Gerriets V , Goyal A , Khaddour K. Tumor necrosis factor inhibitors. [Internet. Accessed July 4, 2025.] Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482425\/"},{"key":"2025120301250843000_52.11.1098.28","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f4b392"},{"key":"2025120301250843000_52.11.1098.29","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac097"},{"key":"2025120301250843000_52.11.1098.30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","article-title":"Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics","volume":"3","author":"Ritchlin","year":"2019","journal-title":"BMC Rheumatol"},{"key":"2025120301250843000_52.11.1098.31","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-016-0440-0"},{"key":"2025120301250843000_52.11.1098.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101009"},{"key":"2025120301250843000_52.11.1098.33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025120301250843000_52.11.1098.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:25:25Z","timestamp":1764753925000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.3899\/jrheum.2025-0029"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0029","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}